At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 518 enrolled
Drug / intervention
AL-4943A Ophthalmic Solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily
In Brief
A Phase 3 clinical trial evaluating AL-4943A Ophthalmic Solution and AL-4943A Ophthalmic Solution Vehicle for Allergic Conjunctivitis. Completed, enrolled 518 participants.
Detailed Summary
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
First PostedOct 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedOct 3, 2012
Enrollment StartOct 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.7 years ago
Interventions
AL-4943A Ophthalmic Solutiondrug
AL-4943A Ophthalmic Solution Vehicledrug
Inactive ingredients used as placebo